Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 10Active not recruiting 3Terminated 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Triple Negative Breast Neoplasms 5Lung Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Inflammatory Breast Neoplasms 3Adenocarcinoma of Lung 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Melanoma 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Turcot syndrome 1Thrombocytosis 1Stages II-III Breast Cancer 1Stage IIIA Lung Non-Small Cell Cancer AJCC v7 1Stage IA Uterine Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Melanoma × Taxes × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡